{"id":"W4391337917","doi":"10.1182/bloodadvances.2023011620","title":"Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results","year":2024,"lang":"en","type":"article","venue":"Blood Advances","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"University of Texas MD Anderson Cancer Center; Genentech; Swedish Orphan Biovitrum; Sierra Oncology; Pfizer; Incyte; CTI Biopharma; Syndax Pharmaceuticals; Bristol-Myers Squibb; Constellation Pharmaceuticals; Agios Pharmaceuticals; Cancer Center, University of Kansas; Astex Pharmaceuticals; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Servier; Memorial Sloan-Kettering Cancer Center; Jazz Pharmaceuticals; Kite Pharma; Shionogi; Amgen; Ohio State University; Karyopharm Therapeutics; MorphoSys; Celgene; AstraZeneca; Astellas Pharma; TG Therapeutics","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Internal medicine; Oncology; Bone marrow","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001738673,0.0002039597,0.0003636633,0.0001431944,0.0000737939,0.00002875847,0.0000420002,0.00003132206,0.00001128669],"category_scores_gemma":[0.0002518362,0.0001330755,0.0000455056,0.0001868332,0.00004036645,0.0001027284,0.000021233,0.00006428321,0.000004094975],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001934713,"about_ca_system_score_gemma":0.00005620595,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000007119462,"about_ca_topic_score_gemma":0.00001846803,"domain_scores_codex":[0.9986502,0.00005399524,0.0003144568,0.0004755963,0.0002912143,0.000214546],"domain_scores_gemma":[0.9986846,0.0007497054,0.00006787222,0.0002044998,0.0001431944,0.0001500974],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.4259331,0.07191643,0.3312037,0.001032256,0.001807226,0.0004110011,0.009823308,0.000118915,0.001390842,0.0005814981,0.002063987,0.1537177],"study_design_scores_gemma":[0.1187382,0.3541982,0.4523572,0.002276541,0.001605773,0.0000209094,0.001468962,0.00007001362,0.03362882,0.0000613741,0.03503639,0.0005376356],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9960061,0.000621286,0.00001131479,0.0004629886,0.00006765675,0.002001782,0.0006426002,0.00004075321,0.0001454604],"genre_scores_gemma":[0.9961427,0.00004897243,0.002898254,0.00008843945,0.00006661088,0.0004643737,0.000058015,0.00002486003,0.0002077352],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3071949,"threshold_uncertainty_score":0.5426661,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02207426763949964,"score_gpt":0.3331461903415754,"score_spread":0.3110719227020758,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}